London, March 16 (EFE). – British pharmaceutical company AstraZeneca announced an agreement with the United States on Tuesday to send an additional 500,000 doses of a potential anti-covid antibody treatment that, if authorized, could protect women from the virus. People who cannot be vaccinated.
In a statement, the company explained that the pact with the Department of Health and Human Services (HHS) and the Department of Defense renews a new October 2020 agreement whereby the United States will receive 100,000 initial doses of the drug “AZD7442” received. , with an option to purchase more in 2021, and committed to supporting the latest phase of clinical studies.
With the additional 500,000 doses announced today and a further 100,000 others agreed in parallel with Defense, AstraZeneca Washington could deliver up to 700,000 doses of the drug by 2021, it says in the note.
“The combination of antibodies with a long-lasting effect has the potential to provide near-instant protection to those who cannot be vaccinated, both to prevent infection and to treat the disease in already infected patients,” said the pharmaceutical company’s CEO , Pascal Soirot. .
“The support of the United States government is critical to accelerate the development of AZD7442, which we believe will be an important tool in the fight against Covid-19,” he added.
The drug, which is designed to reduce resistance to the most potent variants of the virus, is currently being tested in clinical trials involving 9,000 volunteers in various parts of the world, the statement said.
AstraZeneca notes that the total value of the agreements with the US government for the development and delivery of AZD7442 by 2021 is approximately $ 726 million. EFE
ym / er / ah
| K: SOC: SOCIEDAD-SALUD, SALUD |
| Q: SYS: en-ES: 07002000: Sanitation and health: epidemics and pests |
| P: GBR |
03/16 / 10-27 / 21